Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  Advantages of the human tissues the Company distributes;  Plans, costs and expected timeline regarding regulatory approval for PerClot, the distribution of PerClot in certain markets after the requisite regulatory approvals are obtained, and the Companys expectation that it will terminate its minimum purchase requirements after regulatory approval of PerClot;  Expectations and efforts to respond to the FDA questioning related to the revised IDE filed for PerClot;  Benefits of TMR treatment and the Phoenix System;  Estimates regarding the addressable market opportunity for TMR;  Plans related to seeking regulatory approval for the Phoenix System;  Anticipated timing of the PEARL 8.0 launch;  Potential benefits of the Companys surgical adhesives, sealants and hemostats;  Plans related to regulatory approval in certain markets for BioFoam, and the subsequent distribution of BioFoam in those markets after approval, plans to conduct a post-market study in Europe on BioFoam, and the Companys intentions to refund unspent DOD funds related to the BioFoam U.S. clinical trial;  The estimated European market opportunity for cardiovascular and parenchymal tissue sealing;  Commercialization plans for ProPatch;  Plans regarding product enhancements of the HeRO Graft;  Estimates regarding the addressable worldwide market opportunity for the HeRO graft, and the Companys intentions to introduce the HeRO graft into the European Union in mid-2013;  The Companys beliefs regarding production levels of the HeRO graft;  The Companys beliefs that the HeRO graft will fit well within the Companys product portfolio and that a significant opportunity exists to introduce and expand the utilization of the HeRO graft in the U.S.;  Expected benefits of the Companys marketing, educational and technical support efforts;  Plans regarding regulatory approval for CryoValve SGPV and CryoValve SGAV, the benefits of related studies, the expected completion date of the CryoValve SGPV study, and the Companys plans to respond to FDA comments related to the HDE application for CryoValve SGAV;  Expected use of the Companys additional laboratory space;  Anticipated payment of quarterly dividends each year;  The Companys expectations regarding the recoverability and realizability of deferred tax assets;  The Companys estimates of unreported loss liabilities, including unreported tissue processing and product liability claims, the assumptions used to establish those estimates, and the Companys belief that those assumptions provide a reasonable basis for the estimates;  The Companys estimates of fair value of acquired assets, and its belief that the estimates are reasonable;  The expectation that the Company will continue to renew certain acquired contracts and procurement agreements for the foreseeable future; 34  Expectations regarding the recognition of stock compensation expense;  Plans and expectations regarding research and development of new technologies and products;  Expectations that research and development spending will increase materially in 2013;  Expectations regarding business consolidations in the healthcare industry that could exert downward pressure on fees charged by the Company;  Beliefs regarding BioGlue sales, PerClot sales, and handpiece sales and laser console sales, and the factors affecting such sales;  The Companys belief that its SynerGraft processed tissues and the majority of its medical devices will be subject to the new excise tax on the sale of medical devices, and the Companys anticipation that it will not pass along the new excise tax to its customers;  The anticipation that the Companys 2013 tax rate will be favorably impacted by the research and development tax credit, and the belief that cash payments for federal income taxes will be reduced for the 2013 tax year;  Plans related to the debt financing of ValveXchange;  The Companys belief that it will be able to address the FDAs observations in the Form 483 and the Warning Letter and that the related issues will not have a material impact on the Company;  The Companys beliefs regarding the seasonal nature of the demand for some of its products and services;  The adequacy of the Companys financial resources, and its belief that it will have sufficient cash to meet its operational liquidity needs for at least the next twelve months;  The Companys expectation that it will not have significant business development costs related to the acquisitions of Hemosphere and Cardiogenesis in 2013;  Expectations that general, administrative, and marketing expenses will increase in 2013;  Estimates of contingent payments and royalties that may be paid by the Company, and the timing of such payments;  The possibility of a patent infringement lawsuit with Medafor and the Companys belief that PerClot will not infringe Medafors patent;  The impact on cash flows of funding business development activities and the potential need to obtain additional borrowing capacity or financing;  The Companys expectations regarding the source of any future payments related to any unreported tissue processing or product liability claims;  Anticipated impact of changes in interest rates and foreign currency exchange rates;  Plans regarding acquisition and investment opportunities of complementary product lines and companies;  Plans regarding the licensing of the Companys technology to third parties for non-competing uses;  Issues that may impact the Companys future financial performance and cash flows; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including, without limitation, in addition to those specified in the text surrounding such statements, the risk factors discussed in Item 1A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 35 Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the SEC regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2012 (the end of the fiscal year to which this Form 10-K relates). 